This cohort study uses data from an atrial fibrillation registry to describe the proportion of patients on warfarin who had stable INR values over an 18-month period.
This Medical Letter review summarizes the newly available oral anticoagulants and compares them with commonly prescribed warfarin.
This narrative review summarizes stroke risk prediction tools and strategies to prevent stroke in patients with atrial fibrillation.
This Viewpoint discusses optimal dosing recommendations for new anticoagulant agents.
This analysis of data from Danish administrative registries reports that among patients receiving antithrombotic therapy after myocardial infarction, use of nonsteroidal anti-inflammatory drugs was associated with increased risk of bleeding and thrombotic events.
This retrospective cohort study in Germany reports on analyses of the treatment of oral anticoagulation–associated intracerebral hemorrhage and its association with rates of hematoma enlargement, ischemic and hemorrhagic events with or without resumption of oral anticoagulation, and long-term functional outcome.
This randomized trial compared the efficacy and safety of 6 vs 24 months of warfarin treatment for preventing recurrent thromboembolism in patients with a first episode of symptomatic unprovoked pulmonary embolism.
This From the Medical Letter article reviews the pharmacokinetics and indications for edoxaban, an oral anticoagulant for the treatment of venous thromoboembolism and prevention of stroke in patients with AF.